Interpace Biosciences Stock Fundamentals
IDXGDelisted Stock | USD 2.20 0.00 0.00% |
Interpace Biosciences fundamentals help investors to digest information that contributes to Interpace Biosciences' financial success or failures. It also enables traders to predict the movement of Interpace OTC Stock. The fundamental analysis module provides a way to measure Interpace Biosciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Interpace Biosciences otc stock.
Interpace |
Interpace Biosciences OTC Stock Profit Margin Analysis
Interpace Biosciences' Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.
Current Interpace Biosciences Profit Margin | (0.59) % |
Most of Interpace Biosciences' fundamental indicators, such as Profit Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Interpace Biosciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Profit Margin indicator shows the amount of money the company makes from total sales or revenue. It can provide a good insight into companies in the same sector, as well as help to identify trends of a company from year to year.
CompetitionBased on the latest financial disclosure, Interpace Biosciences has a Profit Margin of -0.591%. This is 94.73% lower than that of the Health Care Providers & Services sector and 94.91% lower than that of the Health Care industry. The profit margin for all United States stocks is 53.46% lower than that of the firm.
Interpace Biosciences Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Interpace Biosciences's current stock value. Our valuation model uses many indicators to compare Interpace Biosciences value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Interpace Biosciences competition to find correlations between indicators driving Interpace Biosciences's intrinsic value. More Info.Interpace Biosciences is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Interpace Biosciences' earnings, one of the primary drivers of an investment's value.Interpace Profit Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Interpace Biosciences' direct or indirect competition against its Profit Margin to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Interpace Biosciences could also be used in its relative valuation, which is a method of valuing Interpace Biosciences by comparing valuation metrics of similar companies.Interpace Biosciences is currently under evaluation in profit margin category among its peers.
Interpace Fundamentals
Return On Equity | -2.85 | ||||
Return On Asset | -0.26 | ||||
Profit Margin | (0.59) % | ||||
Operating Margin | (0.28) % | ||||
Current Valuation | 11.72 M | ||||
Shares Outstanding | 4.27 M | ||||
Shares Owned By Insiders | 28.12 % | ||||
Number Of Shares Shorted | 47.35 K | ||||
Price To Earning | (1.07) X | ||||
Price To Book | 10.04 X | ||||
Price To Sales | 0.10 X | ||||
Revenue | 41.31 M | ||||
Gross Profit | 17.95 M | ||||
EBITDA | (9.12 M) | ||||
Net Income | (14.94 M) | ||||
Cash And Equivalents | 1.86 M | ||||
Cash Per Share | 0.44 X | ||||
Total Debt | 9.44 M | ||||
Debt To Equity | 6.55 % | ||||
Current Ratio | 0.61 X | ||||
Book Value Per Share | (14.51) X | ||||
Cash Flow From Operations | (8.72 M) | ||||
Short Ratio | 0.19 X | ||||
Earnings Per Share | (3.12) X | ||||
Target Price | 11.0 | ||||
Number Of Employees | 147 | ||||
Beta | 0.82 | ||||
Market Capitalization | 5.16 M | ||||
Total Asset | 38.43 M | ||||
Retained Earnings | (172.59 M) | ||||
Working Capital | (4.21 M) | ||||
Current Asset | 19.16 M | ||||
Current Liabilities | 23.37 M | ||||
Z Score | -4.6 | ||||
Net Asset | 38.43 M |
About Interpace Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Interpace Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Interpace Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Interpace Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey. Interpace Diag operates under Diagnostics Research classification in the United States and is traded on OTC Exchange. It employs 147 people.
Currently Active Assets on Macroaxis
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in interest. You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Other Consideration for investing in Interpace OTC Stock
If you are still planning to invest in Interpace Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Interpace Biosciences' history and understand the potential risks before investing.
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges |